Navigation Links
Tianyin Pharmaceutical Co., Inc. Announces Cash Dividend to Common Stockholders
Date:3/26/2009

CHENGDU, China, March 26 /PRNewswire-Asia-FirstCall/ -- Tianyin Pharmaceutical, Co., Inc., (NYSE Amex: TPI), a manufacturer and supplier of modernized traditional Chinese medicine ("TCM") based in Chengdu, China, today announced that the Board of Directors declared an annual cash dividend of $0.10 per common share that will be paid quarterly. Subject to approval by a majority of the Company's Series A Preferred Shareholders, the initial dividend of $.025 will be paid to common shareholders of record on April 30, 2009, with the actual distribution occurring on or about June 10, 2009. Dr. Jiang Guoqing, Tianyin's Chairman and Chief Executive Officer, commented, "Our dividend payment is in line with our desire to balance the cash required to operate and grow our business with that of providing and enhancing returns to our shareholders. We have carefully reviewed our current financial position, which includes cash and equivalents of approximately $12.7 million on December 31, 2008, in addition to our projected cash flow from operations, and are confident that Tianyin has sufficient resources to cover our operational and capital expenditures for the foreseeable future. We are committed to act in the best interest of our shareholders and will continue to make significant progress in growing our business."

About Tianyin Pharmaceuticals

Tianyin is a manufacturer and supplier of modernized Traditional Chinese Medicine ("TCM") in China. It was established in 1994 and acquired by the current management team in August 2003. It has a comprehensive product portfolio of 33 modernized TCMs and 5 generic western medicines in the market, 22 of which are listed in the highly selective National Medicine Catalog of the National Medical Insurance Program. Tianyin owns and operates two GMP manufacturing facilities and an R&D platform supported by leading Chinese academic institutions. The Company has a pipeline of 47 pharmaceutical products pending approval. Tianyin has an extensive nationwide distribution network throughout China with a sales force of 720 salespeople. Tianyin is headquartered in Chengdu, Sichuan Province with two manufacturing facilities and a total of 1,365 employees. Tianyin achieved revenue of approximately $33.5 million and net income of approximately $6 million in FY2008 ending June 30, 2008. For more information about Tianyin, please visit http://www.tianyinpharma.com.

Safe Harbor Statement

The Statements which are not historical facts contained in this press release are forward-looking statements that involve certain risks and uncertainties including but not limited to risks associated with the uncertainty of future financial results, additional financing requirements, development of new products, government approval processes, the impact of competitive products or pricing, technological changes, the effect of economic conditions and other uncertainties detailed in the Company's filings with the Securities and Exchange Commission.

    For more information, please contact:

    For the Company:
     Allen Tang, Ph.D., MBA, Assistant to the CEO
     China
     Tel:   +86-158-2122-5642
     Email: Allen.y.tang@gmail.com

    Investors:
    Mr. Matthew Hayden, HC International
    Tel:   +1-561-245-5155
    Email: matt.hayden@hcinternational.net
    Web:  http://www.hcinternational.net


'/>"/>
SOURCE Tianyin Pharmaceutical, Co., Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Tianyin Pharmaceutical Co., Inc. Announces Record Second Quarter 2009 Financial Results
2. Tianyin Pharmaceutical Co., Inc. Begins Initial Share Buyback under its Repurchase Program
3. Tianyin Pharmaceutical Co., Inc. to Host Fiscal Year 2009 First Quarter Earnings Conference Call on Tuesday, November 11, 2008 at 8:30 a.m. EST
4. Tianyin Pharmaceutical Co., Inc. Authorizes $3.0 Million Stock Repurchase Program
5. Tianyin Pharmaceutical Co., Inc. Receives Chinese SFDA Approval for Laonian Kechuan Tablets
6. Tianyin Pharmaceutical Co., Inc. Announces Trading Symbol Error and Correction
7. Tianyin Pharmaceutical Co., Inc. Receives Chinese SFDA Approval for Simvastatin Tablets
8. Tianyin Pharmaceutical Co., Inc. Completes Production for Earthquake
9. Tianyin Pharmaceutical Signs Over 60 New Distribution Agreements with 15 Regional Distributors
10. Tianyin Pharmaceutical Co., Inc. Announces Third Quarter 2008 Financial Results
11. Tianyin Pharmaceutical Co., Inc. to Host Fiscal Year 2008 Third Quarter Earnings Conference Call on Thursday, May 15, 2008 at 9:00 a.m. EDT
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... ... 08, 2016 , ... Steve Helwig & Associates Insurance & Financial, serving the ... has teamed up with Citizens Opposed to Domestic Abuse in support of its efforts ... all those victimized by the fear of violence in their own homes, donations may ...
(Date:2/8/2016)... ... February 08, 2016 , ... ... and relationship-marketing firm, announced today that nominations will be accepted February 8, ... West Awards. , Awards include the Information Security Executive® of the ...
(Date:2/8/2016)... ... , ... Discover the Rocky Mountain region’s longest running and impressive garden and ... also get to see the most incredible gardens and home improvement experts that attend ... Colorado Convention Center - 700 14th St. Denver CO, is an exciting event that ...
(Date:2/8/2016)... Las Vegas, Nevada (PRWEB) , ... February 08, ... ... Co-Founder at RowdMap, Inc., will be speaking on how healthcare companies can use ... project costs, manage the health of a population and intervene and capture the ...
(Date:2/7/2016)... , ... February 07, 2016 , ... ... with the latest techniques and the most minimally invasive approaches. , Women who ... particularly after menopause. Other risk factors include surgery to the pelvic floor, connective ...
Breaking Medicine News(10 mins):
(Date:2/8/2016)... SAN DIEGO , Feb. 8, 2016 /PRNewswire/--  ... have announced that advanced tissue-engineering services are now ... using a groundbreaking new three-dimensional (3D) bioprinting approach ... Regenova® 3D Bio Printer , a state-of-the-art robotic ... Applications has created a powerful pay-for-service bio-printing model ...
(Date:2/8/2016)... Feb. 8, 2016  Avista Pharma Solutions ("Avista Pharma") ... as Chief Financial Officer (CFO). Mr. Setzer is a ... experience in various roles within growing technology and life ... as the Executive Director of Finance at INC Research, ... Raleigh, NC . Previously, Mr. Setzer served as ...
(Date:2/8/2016)... 8, 2016 Velano Vascular, a medical technology ... patients and their practitioners, announced today that the company ... will use the proceeds from this financing, an extension ... January 2015, to support the development and commercialization of ... populations. Philadelphia , and ...
Breaking Medicine Technology: